论文部分内容阅读
本文应用Ｓ－ＥＬＩＳＡ在血吸虫病传播已得到基本控制，而且再感染的可能性非常小的地区，对同批病人治疗前后的ＣＡｇ和ＣＡｂ进行了同步检测，结果：治疗前及治疗后８，１２，１８个月其血清ＣＡｇ阳性率分别为９０．３２％（２８／３１）、８１．８２％（１８／２２）、３３．３３％（９／２７）和１８．１８％（４／２２）。随着治后时间的延长，ＣＡｇ的阴转率显著提高，在治疗后１２个月大部分转阴，１８个月几乎全部转阴，而ＣＡｂ治疗后未见明显下降。同时在达到消灭血吸虫病标准地区对进行考核的１００例自然人群血清ＣＡｇ和ＣＡｂ进行了同步检测，阳性率分别为２％和１０％，两者间差异有显著性（Ｐ＜０．０２５）。提示用Ｓ－ＥＬＩＳＡ检测ＣＡｇ可作为血吸虫病人治疗效果的考核依据，具有较好的考核疗效价值，似可用于现场防治效果的考核。
In this paper, S-ELISA in schistosomiasis transmission has been basically controlled, and the possibility of re-infection in very small areas, the same batch of patients before and after treatment of CAg and CAb were detected simultaneously, before and after treatment 8,12,12 The positive rates of serum CAg in 18 months were 90.32% (28/31), 81.82% (18/22), 33.33% (9/27) and 18.18% (4/22) . With the prolongation of treatment time, the negative conversion rate of CAg increased significantly. Most of the negative conversion of CAg turned negative at the 12th month after treatment, almost completely negative at 18 months, but no significant decrease after CAb treatment. At the same time, the serum CAg and CAb of 100 natural persons who screened out the standard area of eliminating schistosomiasis were detected synchronously. The positive rates were 2% and 10% respectively, with a significant difference (P <0.025). It is suggested that the detection of CAg by S-ELISA can be used as the evaluation basis of the treatment effect of schistosomiasis patients, and has a good evaluation value of curative effect, which may be used for the examination of the field prevention and control effect.